CD8A and neoplasm: Reductions in mTORC1 signaling were validated in RagD-deficient CD8+ T cells from both the MC38 tumor model and the Cl13 chronic infection model, as reflected by decreased phospho-S6 and phospho-4E-BP1 staining (figure 3C, online supplemental figure S2E, F).